Trillium Therapeutics (TRIL) Trading Up 5.7%
Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) shares were up 5.7% on Tuesday . The company traded as high as $0.40 and last traded at $0.37. Approximately 1,123,072 shares traded hands during trading, an increase of 28% from the average daily volume of 879,308 shares. The stock had previously closed at $0.35.
A number of research analysts have weighed in on TRIL shares. HC Wainwright reduced their target price on Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Zacks Investment Research upgraded Trillium Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a report on Thursday, April 25th.
The firm has a market capitalization of $7.38 million, a price-to-earnings ratio of -0.16 and a beta of 2.44.
Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 16,541 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Trillium Therapeutics in the 4th quarter worth approximately $35,000. Jane Street Group LLC bought a new stake in shares of Trillium Therapeutics in the 4th quarter worth approximately $43,000. Oxford Asset Management LLP boosted its position in shares of Trillium Therapeutics by 64.0% in the 1st quarter. Oxford Asset Management LLP now owns 93,589 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 36,534 shares in the last quarter. Finally, Morgan Stanley boosted its position in shares of Trillium Therapeutics by 25.2% in the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock worth $2,068,000 after purchasing an additional 71,860 shares in the last quarter. Hedge funds and other institutional investors own 33.00% of the company’s stock.
Trillium Therapeutics Company Profile (NASDAQ:TRIL)
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Coverage Ratio
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.